Drugs / Neuradiab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00906516 | May 2009 → Sep 2010 | brain neoplasm | Bradmer Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00615186 | Jun 2008 → Aug 2013 | glioblastoma | Bradmer Pharmaceuticals Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Neuradiab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00906516 ↗ |
| Action | Deplete | “In this way, it is anticipated that residual tumor cells, which represent the primary reason for treatment failure using conventional therapy, will be destroyed, thus...” NCT00615186 ↗ |
| Modality | Monoclonal antibody | “131I-labeled anti-tenascin murine monoclonal antibody” NCT00906516 ↗ |
| Route | Other | “single intracavitary dose of Neuradiab®” NCT00906516 ↗ |